King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"
This article was originally published in The Pink Sheet Daily
Executive Summary
Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.
You may also be interested in...
Sandoz Tries An Authorized Generic Argument To Relaunch At-Risk Skelaxin
A temporary restraining order is blocking Sandoz's generic version of King's muscle relaxant, but CorePharma's launch of an authorized generic means the TRO should be lifted, Sandoz argues.
Sandoz Tries An Authorized Generic Argument To Relaunch At-Risk Skelaxin
A temporary restraining order is blocking Sandoz's generic version of King's muscle relaxant, but CorePharma's launch of an authorized generic means the TRO should be lifted, Sandoz argues.
Regulatory Growing Pains: An Interview With King CEO Brian Markison (Part 2)
King Pharmaceuticals is in the center of a pivotal shift in the regulation of addictive pain therapies in the U.S. The company hopes to keep getting new products through FDA while helping to shape a class-wide opioid REMS. That is quite an agenda for 2010.